Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L. Sos, Roman K. Thomas, Stefanie Fischer et al.|Proceedings of the National Academy of Sciences|2009Cited by 255
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Peter Vermaelen et al.|Clinical Cancer Research|2012Cited by 69
Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesisAdriana Soler, Bart Vanhaesebroeck, Helena Serra et al.|The Journal of Experimental Medicine|2013Cited by 69
Supplementary Figure Legend from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0